spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Pompe disease 

 HSMN NewsFeed - 20 Jan 2023
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Aug 2021
FDA Approves New Treatment for Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jul 2021
Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST(R) in the Middle East and North Africa
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2019
Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Nov 2018
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Aug 2018
Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
Biopharmaceuticals Regenerative Medicine FDA
 HSMN NewsFeed - 5 Jun 2018
Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Dec 2017
Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Nov 2017
Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2017
Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2017
Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Mar 2017
Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
Biopharmaceuticals
 HSMN NewsFeed - 6 May 2016
Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Jan 2016
Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2015
Amicus Therapeutics Provides U.S. Regulatory Update for Migalastat Monotherapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Sep 2015
Audentes Therapeutics Expands Senior Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2015
Amicus Therapeutics Strengthens Executive Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2015
Amicus Therapeutics Submits Marketing Authorization Application (MAA) for Full Approval of Fabry Monotherapy Galafold(TM) (Migalastat) in European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2014
Audentes Therapeutics Raises $42.5 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Aug 2014
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
Biopharmaceuticals
 HSMN NewsFeed - 13 Jan 2014
BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2013
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 3 Sep 2013
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jul 2013
Audentes Therapeutics Raises $30 Million in Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Apr 2013
Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Sep 2012
BioMarin Names Jeff Ajer Senior Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2011
Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2011
AVI BioPharma Names Ed Kaye, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2010
BioMarin Acquires ZyStor Therapeutics, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 May 2010
Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2009
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2008
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Apr 2008
Genzyme Provides Update on Myozyme(R) Manufacturing
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2007
Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Oct 2007
Genzyme Receives Approval to Market Elaprase(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Mar 2007
Amicus Therapeutics Announces Return of John F. Crowley as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2007
Amicus Therapeutics Receives Grant From Michael J. Fox Foundation for Parkinson's Research
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2006
Amicus Therapeutics Appoints Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Sep 2006
Amicus Therapeutics Raises $60 Million Series D Financing; Company Also Makes Two Key Executive Appointments
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 24 Jul 2006
Genzyme Receives Approval for Additional Manufacturing at Ireland Plant
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Jul 2006
Amicus Therapeutics Adds Glenn P. Sblendorio to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2006
FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2006
European Commission Approves Genzyme's Myozyme(R)
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 27 Jan 2006
Myozyme(R) Receives Positive Opinion from European Regulatory Committee
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Jan 2006
Genzyme Provides Update on U.S. Marketing Application for Myozyme(R)
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
Pompe disease
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.